top of page
Search

Oral antiviral therapy for COVID-19? update to our management guidelines - Jan 26, 2022

Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!

 
 
 

Recent Posts

See All
Linezolid TDM

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...

 
 
 
MUHC ASP annual report 2022-2023

The ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....

 
 
 
S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...

 
 
 

Comments

bottom of page